Unexpected Positive Effects of Rituximab and Corticosteroids on COVID-19 in a Patient Suffering from Granulomatosis with Polyangiitis.

COVID-19 cytokine storm granulomatosis with polyangiitis immunosuppressive drugs rituximab

Journal

Advanced biomedical research
ISSN: 2277-9175
Titre abrégé: Adv Biomed Res
Pays: India
ID NLM: 101586897

Informations de publication

Date de publication:
2021
Historique:
received: 20 10 2020
revised: 26 04 2021
accepted: 26 04 2021
entrez: 11 11 2021
pubmed: 12 11 2021
medline: 12 11 2021
Statut: epublish

Résumé

The COVID-19 pandemic has raised concerns among physicians and patients with autoimmune disorders about how this viral infection affects the patients receiving immunosuppressive drugs. There are speculations about a higher incidence and severity of COVID-19 in patients receiving a variety of immunosuppressant drugs. However, we reported the rapid recovery from COVID-19 in a 67-year-old male with granulomatosis with polyangiitis who did not experience severe symptoms of the COVID-19 as expected, despite having a history of serious lung involvement due to the autoimmune disease. He received conventional medications to treat COVID-19, though he had been receiving rituximab and corticosteroids before the onset of COVID-19 symptoms. Prevention of the cytokine storm caused by SARS-CoV-2 infection owing to taking the immunosuppressive drugs (rituximab and corticosteroids) could be a reason for these unexpected observations. Therefore, this case showed that taking immunosuppressive drugs is unlikely to be directly related to the increased severity of COVID-19.

Identifiants

pubmed: 34760807
doi: 10.4103/abr.abr_266_20
pii: ABR-10-25
pmc: PMC8531733
doi:

Types de publication

Case Reports

Langues

eng

Pagination

25

Informations de copyright

Copyright: © 2021 Advanced Biomedical Research.

Déclaration de conflit d'intérêts

There are no conflicts of interest.

Références

Semin Respir Crit Care Med. 2018 Aug;39(4):434-458
pubmed: 30404111
Int J Infect Dis. 2011 Jan;15(1):e2-16
pubmed: 21074471
Rheum Dis Clin North Am. 2016 Feb;42(1):157-76, ix-x
pubmed: 26611557
Intractable Rare Dis Res. 2016 May;5(2):61-9
pubmed: 27195187
Biologics. 2012;6:31-5
pubmed: 22355257
J Pediatr. 2003 Sep;143(3):363-7
pubmed: 14517521
Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32
pubmed: 22390970
Int Anesthesiol Clin. 2007 Spring;45(2):27-37
pubmed: 17426506
Am J Transplant. 2006 May;6(5 Pt 1):859-66
pubmed: 16611321
Chest. 1995 Nov;108(5):1315-25
pubmed: 7587435
N Engl J Med. 2020 Jun 18;382(25):e102
pubmed: 32356626
Int J Surg. 2020 Apr;76:71-76
pubmed: 32112977
Ann Rheum Dis. 2021 Jan;80(1):e10
pubmed: 32312768
Br J Pharmacol. 2006 Jun;148(3):245-54
pubmed: 16604091
Ann Rheum Dis. 2020 May;79(5):667-668
pubmed: 32241793
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
Cancer Immunol Immunother. 2012 Aug;61(8):1233-41
pubmed: 22249775
Mediators Inflamm. 2016;2016:1796094
pubmed: 27555669

Auteurs

Mansour Salesi (M)

Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Behrokh Shojaie (B)

Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Zohre Naderi (Z)

Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Classifications MeSH